skip to content
Stories
Careers
Contact
About Roche
About Roche
Business
Governance
Sustainability
Roche Global Citizenship
Strategy
Leadership
History
Solutions
Solutions
Focus areas
Pharma solutions
Diagnostic solutions
Product Development Pipeline
Innovation
Innovation
Partnering
Ethical standards
Team and structure
Innovation process
Clinical trials
Investors
Investors
Investor updates
Investor events
Reporting
Finance Information Tool
Share and Bond information
Download center
Frequently asked questions
Media
Media
Media releases
Media events
Media statements
Media library
About Roche
About Roche
Business
Business
Diagnostics
Pharma
Governance
Governance
Annual general meetings
Board of directors
Committees
Executive committee
Code of conduct
Sustainability
Sustainability
Approach
Goals and performance
ESG index
Safety health and wellbeing
Roche Global Citizenship
Roche Global Citizenship
Arts and culture
Community disaster relief
Humanitarian social development
React
Rebuiding communities
Science and education
Strategy
Leadership
History
Solutions
Solutions
Focus areas
Focus areas
Cardiometabolic
Haematology
Diabetes
Immunology
Infectious diseases
Inflammatory bowel diseases
Neurology
Oncology
Ophthalmology
Respiratory
Women's health
Pharma solutions
Pharma solutions
Safety reporting
Diagnostic solutions
Diagnostic solutions
Safety officers
Product Development Pipeline
Innovation
Innovation
Partnering
Partnering
Pharma
Diagnostics
Areas of interest
Ethical standards
Ethical standards
Advisory
Animal research
Genetics
Team and structure
Team and structure
R&D locations
Innovation process
Clinical trials
Investors
Investors
Investor updates
Investor events
Reporting
Finance Information Tool
Share and Bond information
Download center
Frequently asked questions
Media
Media
Media releases
Media events
Media statements
Media library
Stories
Careers
Contact
worldwide
Media
Media statements
Roche confirms participation in FDA Oncologic Drug Advisory meeting on 20 May 2025
May 07, 2025
PDF
Roche’s Greenhouse Gas Reduction Targets Validated by the Science Based Targets initiative (SBTi)
April 02, 2025
PDF
WHO approves Roche’s mpox diagnostic test for emergency use, boosting global access
October 21, 2024
PDF
Roche submits science-based targets for net zero by 2045
October 11, 2024
PDF
Roche enters into a definitive agreement with Lonza, which will acquire the Genentech manufacturing facility in Vacaville, California, USA
March 20, 2024
PDF
Roche actively advances sector decarbonisation ahead of COP28
November 29, 2023
PDF
Roche launches a new addition to the cobas® connection modules, the CCM Vertical, helping to improve laboratory efficiency
August 17, 2023
PDF
FDA grants accelerated approval of Elevidys™, the first gene therapy to treat
June 22, 2023
PDF
Roche to divest legacy Genentech facility in Vacaville, California, as part of long-term strategy to evolve manufacturing capabilities
May 31, 2023
PDF
Adoption of the Resolution on Strengthening Diagnostics capacity at the 76th World Health Assembly
May 26, 2023
PDF
CHMP recommends Ronapreve for the treatment of hospitalised COVID-19 patients
April 27, 2023
PDF
Roche statement on FDA Oncologic Drug Advisory meeting on 9 March 2023
January 25, 2023
PDF
Roche provides update on Tecentriq US indication for previously untreated metastatic bladder cancer
November 29, 2022
PDF
Roche signs up to the Science Based Targets initiative and the Sustainable Markets Initiative to further deepen the commitment to climate actions
November 17, 2022
PDF
Roche and the World Health Organization partner to improve access to Actemra®/RoActemra® (tocilizumab) for COVID-19 in low- and middle-income countries
March 24, 2022
PDF
Additional studies confirm Roche SARS-CoV-2 Rapid Antigen Tests’ sensitivity against Omicron variant
January 18, 2022
PDF
Viruses mutate over time, and SARS-CoV-2 is no exception
January 06, 2022
PDF
How Roche tests and medicines continue to play a key role as pandemic evolves
December 22, 2021
PDF
Ronapreve does not retain neutralising activity against the Omicron variant
December 16, 2021
PDF
Roche statement on termination of partnership with Atea Pharmaceuticals to develop AT-527
November 16, 2021
PDF
Roche statement on follow-up analysis of Ronapreve phase III prevention trial
November 08, 2021
PDF
WHO recommends the use of Ronapreve™ (casirivimab and imdevimab) in COVID-19 patients
September 24, 2021
PDF
Roche statement on global supply constraints of Actemra/RoActemra
August 16, 2021
PDF
World Health Organization issues new treatment recommendations for the clinical management of COVID-19
July 07, 2021
PDF
Roche statement on the preliminary phase III data from UK University of Oxford-led RECOVERY trial for casirivimab and imdevimab
June 16, 2021
PDF
Roche statement on FDA Oncologic Drug Advisory Meetings on 27–29 April 2021
March 12, 2021
PDF
Roche statement on the European Medicines Agency (EMA) commencement of review for Regeneron’s antibody cocktail (casirivimab and imdevimab)
February 01, 2021
PDF
Roche statement on casirivimab and imdevimab data in preventing COVID-19 infections within households
January 26, 2021
PDF
Roche statement on casirivimab and imdevimab data in hospitalised patients
December 30, 2020
PDF
Roche statement on new variants of SARS-CoV-2 found in the UK
December 23, 2020
PDF
Roche statement on FDA acceptance of casirivimab and imdevimab (REGNCOV2) EUA in the US
November 22, 2020
PDF
Changes recommended to ongoing REGN-COV2 study in hospitalized patients by Independent Data Monitoring Committee
October 30, 2020
PDF
Roche statement on REGN-COV2 data in non-hospitalised patients
October 28, 2020
PDF
Roche statement on REGN-COV2 US Emergency Use Authorization Request
October 08, 2020
PDF
Roche statement regarding UK diagnostics products supply issue
October 07, 2020
PDF
Roche statement on REGN-COV2 virology phase II data
September 29, 2020
PDF